tiprankstipranks
Bio-Techne (DE:TE1)
XETRA:TE1
Germany Market

Bio-Techne (TE1) Blogger Opinions & Sentiment

1 Followers

Blogger Sentiment

Bearish: 75.00%
Sector Average
Neutral
DE:TE1 Blogger sentiment is based on 6 Blogger Opinions. The Blogger sentiment is more Bullish than other stocks in the Healthcare sector.

Blogger Article Distribution

ArticleDistribution
25% Zacks
25% GuruFocus
25% Investing
25% Others
The distribution of articles among the main online Financial Blogging platforms.

Top Blogger Bearish Predictions

Techne Tech Q4 Earnings Meet Estimates
Zacks
Goldman Sachs Reports Unprecedented Hedge Fund Retreat from Tech Stocks
GuruFocus
Recent negative articles by top bloggers.

Top Blogger Bullish Predictions

Bio-Techne upgraded to Outperform at RBC on strong growth potential
SeekingAlpha
Recent positive articles by top bloggers.

Financial Blogger Predictions​​

Blogger Performance
Any
Any
Blogger Sentiment
Any
Any
Blogger Name
Blogger Rank
Blog
Date
Blogger Sentiment​
Article
Follow

FAQ

What do Seeking Alpha bloggers think of DE:TE1?
Seeking Alpha’s Nilanjana Basu has a Bullish Sentiment.
    What do Motley Fool contributors think of DE:TE1?
    Currently there's no blogger sentiment for DE:TE1.
    What Is DE:TE1’s Blogger Sentiment?
    DE:TE1’s Blogger Sentiment is Neutral.
      What was the most recent blogger prediction for DE:TE1?
      The most recent blogger prediction for DE:TE1 was made by NASDAQ:TECH, who was Neutral on the stock.
        How can I follow the stock ratings of top Top Financial Bloggers?
        Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Stocks with the Highest Top Blogger Ratings in the Healthcare sector
          CADLCandel Therapeutics
          VERAVera Therapeutics
          MLTXMoonLake Immunotherapeutics
          GTBIFGreen Thumb Industries
          DFTXDefinium Therapeutics